Latest Natalizumab Stories
ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of CimziaÂ® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients were previously treated with infliximab (IFX) or infliximab-naive.
ATLANTA, April 29 /PRNewswire/ -- Studies and analyses of the Crohn's Disease (CD) treatment CimziaÂ® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010. "Cimzia data at this year's DDW provide important and positive clinical insights, namely, that Cimzia offers long-term efficacy in multiple patient populations," said Cem Kayhan, MD, Associate Medical Director at UCB.
EXTON, Pa., April 26 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis.
Data also showed reduced fatigue and improved cognition.
A study led by Mayo Clinic suggests remission from Crohn's disease may be more likely if patients get biologic therapy combined with immune-suppressing drugs first instead of immune-suppressing drugs alone.
WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018.
MILWAUKEE, Jan. 25 /PRNewswire/ -- Today the NRI Welfare Society of India recognized Bhupendra Khatri, M.D., of Aurora St. Luke's Medical Center with its prestigious Hind Rattan Award. (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b) Dr.
SILVER SPRING, Md., Jan. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS).
CAMBRIDGE, Mass., Jan.
Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRIÂ® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.
- A person in a secondary role, specifically the second most important character (after the protagonist).